Abivax appoints Michael Ferguson as Chief Commercial Officer

April 18, 2023

Michael Ferguson has a strong track record in the biopharmaceutical industry, having held senior positions for commercialization and marketing of drugs in the field of Gastroenterology and specifically in Inflammatory Bowel Diseases (IBD)

As CCO of Abivax, Michael Ferguson will be leading the market development of obefazimod in IBD, starting with ulcerative colitis

PARIS, France, April 18, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Michael Ferguson as new Chief Commercial Officer, effective immediately, and he will be based at the new Abivax subsidiary on the US East Coast. Therefore, Pierre Courteille will be focusing on business development activities and is appointed Chief Business Officer. Abivax is strengthening its expertise in the commercial and business development field to foster the evolution of the Company towards future commercialization of obefazimod.

Michael Ferguson brings over 22 years of experience in the biopharmaceutical industry, with an extensive track record in the field of Gastroenterology (GI) and Inflammatory Bowel Disease (IBD). He has spent the last 16 years of his career in large pharmaceutical and biotech companies, including 13 years in leading commercial positions at Shire/Takeda, followed by Arena Pharmaceuticals, where he served as Vice President Global Commercial Marketing and Planning and specifically as Global Commercial Lead for Etrasimod across all GI Indications. Michael holds both a B.S. and an M.B.A with honors in Finance from the Pennsylvania State University as well as a post graduate degree from St. Joseph's University, Philadelphia, in Pharmaceutical Marketing.

Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax, said: *"I am delighted that Michael Ferguson will further strengthen Abivax's executive team and contribute to the success of the Company with his extensive experience in global commercialization and marketing, especially in the United States. As Abivax's CCO, he will be leading the global positioning of our lead drug candidate and prepare the ground for commercial launch and market development of obefazimod for the treatment of ulcerative colitis. Along with Michael Ferguson as CCO, the Company has a strong, internationally recognized experienced and diversified senior management team to lead obefazimod through the final development steps and, if successful, towards the market and the patients who urgently need new treatments."*

Michael Ferguson, new CCO of Abivax, commented: *"I am very excited to join the Abivax team with the ongoing Phase 3 clinical program with obefazimod. Based on my experience and the recently reported and very encouraging results of UC patients treated for two years with obefazimod, I believe that the molecule has what it takes to become a new therapeutic option for patients suffering from UC and IBD generally. From a global marketing perspective, obefazimod's convenient once-daily oral administration will be a big advantage for both patients and gastroenterologists."*

*****

About Abivax (www.abivax.com)

Abivax is a Phase 3 clinical stage biotechnology company, focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases. Abivax, founded by Truffle Capital, is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of ulcerative colitis. More information on the company is available at www.abivax.com. Follow us on Twitter @ABIVAX_.

Contacts

Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63

Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310

Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22

Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24

Public Relations France
Primatice
Thomas Roborel de Climens
thomasdeclimens@primatice.com
+33 6 78 12 97 95

Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858

DISCLAIMER

This press release contains forward-looking statements, forecasts and estimates (including patient recruitment) with respect to certain of the Company's programs. Although Abivax' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its registration document (Document d'Enregistrement Universel). These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.